Prometheus Labs, Medco Research Partner on Companion Dx for IBD | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Prometheus Laboratories and Medco Research Institute today announced a deal to evaluate Prometheus' test for identifying patients who may benefit from a therapy for inflammatory bowel disease.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.